Loading market dashboard
BioLife Solutions, Inc.
BLFSHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
On May 28, 2026, BioLife Solutions Inc (BLFS) shares rose 3.1% to a current price of $25.25. This movement comes amid a 52-week range that sees a high of $29.62
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.
Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report) shares crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $23.73 and traded as low as $21.29. BioLife Solutions shares last traded at $21.72, with a volume of 483,605 shares. Wall Street Analyst Weigh In Several research
BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026.
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials.
The average of price targets set by Wall Street analysts indicates a potential upside of 70.8% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Capricorn Fund Managers Ltd purchased a new stake in shares of BioLife Solutions, Inc. (NASDAQ: BLFS) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 378,550 shares of the medical equipment provider's stock, valued at approximately $9,153,000. BioLife Solutions comprises 2.2% of Capricorn
The heavy selling pressure might have exhausted for BioLife Solutions (BLFS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
